7Sionov E,Segal E. Polyene and cytokine treatment of experimental aspergillosis[J].FEMS Immunol Med Microbiol, 2003,39( 3 ) : 221-227.
8Kalin M, Bjorkholm M.prophylactic and empirical treatment of mycoses in neutropenic fever:Report and comments on meta-analysis[J].Lakartidningen, 2001,98(16) : 1899-1903.
5Zer Y, Balci I, Meric G. Identification and antifungal susceptibility of Candida isolated from intensive care unit patients. New Microbiol, 2002, 25(4): 489-494.
6Foongladda S, Sakulmaiwatana P, Petlum P, et al. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. J Med Assoc Thai, 2004,87 (1) :92-99.
7Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother, 2002, 49 (Suppl 1 ): 7-10.
8Mukherjee PK, Chandra J, Kuhn DM, et al. Mechanism of fluconazole resistance in Candida albicans biofilms:phase-specific role of efflux pumps and membrane sterols. Infect Immun, 2003, 71 (8):4333-4340.
9Pinjon E, Moran GP, Jackson C J, et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother, 2003, 47 (8) :2424- 2437.
10el Mahallawy HA, Attia I, Ali el Din NH, et al. A prospective study on fungal infection in children with cancer. J Med Microbiol, 2002,51(7) :601-605.
